Nymox Pharmaceutical Corp (NYMX) 2.43 $NYMX Nymox

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nymox Pharmaceutical Corp (NYMX) 2.43 $NYMX

Nymox Pharmaceutical (NYMX) Stock Higher on Positive Test Results
at The Street - 1 hr 41 mins ago
Nymox Pharmaceutical (NYMX) shares continue to climb on promising BPH treatment candidate results.
NYMX: 2.43 (-0.11)

Nymox July 27 Webcast of New BPH Clinical Trial Results Posted Today Online
GlobeNewswire - 2 hrs 25 mins ago
Nymox's (NASDAQ:NYMX) July 27 webcast of news and discussion by experts of the Company's new clinical trial results can be viewed at http://limelightdc.com/clientarea/nymox_inves...r_vod.html. The link is also available at the Company's website.
NYMX: 2.43 (-0.11)

Nymox Pivotal Phase 3 NX-1207 BPH Extension Trial Successfully Meets Primary Endpoint. Company Plans to File for Regulatory Approvals for Fexapotide Triflutate (NX-1207).
GlobeNewswire - Mon Jul 27, 8:30AM CDT
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that the Company's U.S. long-term extension prospective double-blind Phase 3 BPH studies NX02-0017 and NX02-0018 of fexapotide triflutate (NX-1207) for BPH have successfully met the pre-specified primary endpoint of long-term symptomatic statistically significant benefit superior to placebo. Fexapotide showed an excellent safety profile with no evidence of drug-related short-term or long-term toxicity nor any significant related molecular side effects in the 2 studies (n=978).
NYMX: 2.43 (-0.11)

Nymox Appoints Cutler & Co. as Auditor
GlobeNewswire - Thu Jul 16, 5:03PM CDT
On July 15, 2015, the Board of Directors of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) approved the engagement of Cutler & Co., LLC to serve as the Company's new independent registered public accounting firm to replace KPMG LLP. Prior to the date of Cutler's engagement, the Company has not consulted with Cutler regarding (i) the application of accounting principles to a specific completed or contemplated transaction, (ii) the type of audit opinion that might be rendered on the Company's financial statements and neither a written report was provided to the registrant nor oral advice was provided that the new accountant concluded was an important factor considered by the registrant in reaching a decision as to the accounting, auditing or financial reporting issue; or (iii) any matter that was either the subject of a disagreement.
NYMX: 2.43 (-0.11)

Nymox Announces Appointment of Erik Danielsen as CFO
GlobeNewswire - Mon Jul 13, 12:15PM CDT
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce the appointment of Erik Danielsen as Chief Financial Officer of the Company. Mr. Danielsen is a highly experienced financial analyst with special expertise in emerging health care companies, and with extensive international business knowledge.
NYMX: 2.43 (-0.11)

Benign Prostatic Hyperplasia Pipeline Report 2015 - 26 Companies & 35 Drug Profiles
M2 - Fri Jul 10, 3:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k3hn53/benign_prostatic) has announced the addition of the "Benign Prostatic Hyperplasia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Addex Therapeutics Ltd - AmVac AG - AndroScience Corporation - Aphios Corporation - Ausio Pharmaceuticals, LLC - Biolab Sanus Farmaceutica Ltda. - Chong Kun Dang Pharmaceutical Corp. - Corium International, Inc. - Curadis GmbH - Euroscreen S.A. - Hanmi Pharmaceuticals, Co. Ltd. - IntelGenx Corp. - Jeil Pharmaceutical Co., Ltd. - KAEL-GemVax Co., Ltd. - Kaken Pharmaceutical Co., Ltd. - Meiji Seika Pharma Co., Ltd. - Mezzion Pharma Co. Ltd. - Neurocentrx Pharma Ltd. - Nymox Pharmaceutical Corporation - Ono Pharmaceutical Co., Ltd. - Quest PharmaTech Inc. - SK Chemicals Co., Ltd. - SOM Innovation Biotech SL - Sophiris Bio, Inc. - Yungjin Pharm Ind. Co., Ltd. Drug Profiles - (tamsulosin hydrochloride dutasteride) - ADX-68692 - AMV-110 - ASC-JM.X2 - AUS-131 - BL-214 - CKD-902 - CR-1493 - Drugs for Burning Sensation - ESN-364 - HCP-1303 - HIP-1402 - INT-0031 - JLP-1207 - L-1AD3 - MCS-2 - NCE-403 - NX-1207 - ONO-8430506 - S-40542 - SL-052 - Small Molecules to Antagonize GnRH for Women's Health, BPH and Oncology - Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - SOM-2391 - SOM-2393 - Sperol - Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - talaporfin sodium - tamsulosin hydrochloride - tamsulosin hydrochloride CR - tertomotide - topsalysin - udenafil - YBH-1603 - YOB-1604 For more information visit http://www.researchandmarkets.com/research/k3..._prostatic
CORI: 13.76 (+0.31), SPHS: 0.89 (+0.03), NYMX: 2.43 (-0.11), ABBV: 70.88 (+1.54)

Nymox Announces $850,000 Financing
GlobeNewswire - Tue Jun 16, 11:11AM CDT
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce that it has recently completed financing for a total of $850,000 at prices of $1.25-$1.66. The financing consisted of a private placement of 400,000 shares with a European investor at $1.25 per share and an equity line drawdown from the Company's existing facility consisting of 217,122 shares priced at $1.66 per share. There were no warrants attached to the transactions.
NYMX: 2.43 (-0.11)

BUYINS.NET: NYMX Removed From Naked Short Lists Today
M2 - Mon May 25, 9:25AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Removed From the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Nymox Pharmaceutical Corp (NASDAQ:NYMX). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
NYMX: 2.43 (-0.11)

BUYINS.NET: NYMX Added To Naked Short Lists Today
M2 - Mon May 18, 9:32AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Added To the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Nymox Pharmaceutical Corp (NASDAQ:NYMX). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
NYMX: 2.43 (-0.11)

Nymox Pharma reports Q1 results
Seeking Alpha - at Seeking Alpha - Fri May 15, 4:45PM CDT

NYMX: 2.43 (-0.11)

Nymox Reports First Quarter 2015 Financial Results
GlobeNewswire - Fri May 15, 4:32PM CDT
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the first quarter of 2015 prepared in accordance with International Financial Reporting Standards. Nymox reported a net income of $1,576,551, or $0.04 per share for the quarter ended March 31, 2015, compared to a net loss of $2,592,816, or $0.07 per share for same period in 2014. The net income in 2015 is attributable to the recognition of $2,508,533 as revenue relating to the upfront payment received from Recordati in December 2010 compared with $654,400 for the quarter ended March 31, 2014. The increase of $1,854,133 in the first quarter of 2015 is due to the fact that the initial estimated service period of five years to recognize the upfront payment was modified following Recordati's termination of the European clinical trial. Consequently, the Corporation recognized, as revenue, an amount of $2,508,533 which represented the remaining deferred revenue relating to the upfront payment received in December 2010.
NYMX: 2.43 (-0.11)

Midday Gainer / Losers
Seeking Alpha - at Seeking Alpha - Thu May 14, 11:45AM CDT

KNDI: 7.12 (+0.28), INVE: 4.57 (+0.16), JONE: 7.40 (+0.25), QKLS: 1.72 (-0.03), HIIQ: 4.52 (+0.02), NYMX: 2.43 (-0.11), EGAN: 4.53 (-0.04), GEVO: 2.09 (+0.06), HNR: 1.18 (+0.07), FES: 1.11 (+0.03), ONTY: 3.49 (+0.14), GLPG: 55.19 (+0.40), OHGI: 2.17 (-0.11), ATOS: 0.98 (+0.04), CLVS: 86.48 (+3.56), PSTR: 1.99 (+0.04), AKER: 4.32 (+0.14), RVNC: 32.67 (+0.98), GIGA: 1.83 (+0.13), DSCO: 0.55 (+0.04)

Consumers Growing Interest in a Healthy Lifestyle Leads to Increase in Nutritional Supplement Revenues as Distribution Channels Open Up in North America
PR Newswire - Tue May 12, 7:25AM CDT
Consumers across various age groups are leading a healthier life by eating right, exercising and consuming supplements to meet their recommended dietary allowances. Nutritional supplements are readily available at a growing number of stores and fitness centers that enable consumers to stay healthy as Companies look for innovative ways to increase distribution on a Global level. Companies in focus today are: Axxess Pharma Inc. (OTC: AXXE), Vitamin Shoppe, Inc. (NYSE: VSI), Nymox Pharmaceutical Corporation (NASDAQ: NYMX), MusclePharm Corporation (OTC: MSLP) and Natural Health Trends Corp. (NASDAQ: NHTC)
VSI: 34.69 (-0.46), NHTC: 24.87 (+0.38), WWE: 16.56 (+0.55), NYMX: 2.43 (-0.11)

Recent Highlights from the Healthcare Sector: Complementary Research on BioMarin, Seattle Genetics, Globus Medical, Nymox and Progenics
PR Newswire - Mon May 11, 7:50AM CDT
Editor Note: For more information about this release, please scroll to bottom.
PGNX: 9.48 (+0.35), BMRN: 145.58 (+1.26), GMED: 27.14 (-0.02), SGEN: 49.12 (+1.06), NYMX: 2.43 (-0.11)

Pharma Companies Beginning to Mix Diversification by Expanding into the Multi-Billion Dollar Nutritional & Nutraceutical Supplements Market as Projected Growth Opportunities Continue to Rise
PR Newswire - Wed May 06, 7:45AM CDT
Global pharmaceutical market moves beyond traditional prescription-only medicines as the nutritional sector for weight management, sports nutrition and additional supplements & nutraceuticals accelerate with International growth opportunities. Pharma Companies in focus today are: Axxess Pharma Inc. (OTC: AXXE), Nymox Pharmaceutical Corporation (NASDAQ: NYMX), AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), NuVasive, Inc. (NASDAQ: NUVA) and Mylan N.V. (NASDAQ: MYL).
WWE: 16.56 (+0.55), MYL: 55.72 (-0.65), AMAG: 66.63 (+1.56), NYMX: 2.43 (-0.11), NUVA: 50.04 (+0.45)

Nasdaq stocks posting largest volume increases
AP - Tue Apr 21, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
FARO: 38.66 (+0.82), ENZN: 1.35 (unch), CDZI: 8.73 (+0.32), BNSO: 1.30 (unch), DTLK: 6.88 (-0.06), NYMX: 2.43 (-0.11), IDSY: 5.25 (+0.04), VLTC: 7.63 (-0.51), TLOG: 2.46 (+0.01), UCTT: 7.30 (+0.08), OBAS: 7.31 (-0.19)

Nymox Pharmaceuticals (NYMX) Stock Drops Today Following Monday's Climb
at The Street - Tue Apr 21, 10:25AM CDT
Shares of Nymox Pharmaceuticals (NYMX) were down in late morning trading Tuesday as investors took some profits following the stock's surge on Monday.
NYMX: 2.43 (-0.11)

Nymox Pharmaceuticals (NYMX) Stock Spikes Today on Prostate Cancer Trial Data
at The Street - Mon Apr 20, 11:11AM CDT
Shares of Nymox Pharmaceuticals (NYMX) surged Monday after the company announced long-term clinical trial results from its NX-1207 Phase 2 prostate cancer study NX03-0040.
NYMX: 2.43 (-0.11)

Nymox Pharma's NX-1207 shows long-term benefits in prostate cancer; Shares jump
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 10:08AM CDT

NYMX: 2.43 (-0.11)

Nymox Announces New Prostate Cancer Clinical Trial Results
GlobeNewswire - Mon Apr 20, 9:00AM CDT
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today long-term clinical trial results from the Company's NX-1207 Phase 2 prostate cancer study NX03-0040. The new results demonstrate statistically significant (p=.0067) better outcomes at up to 2.8 years for NX-1207 treated patients compared to controls. Trial participants included 146 patients with low grade localized prostate cancer at 44 U.S. investigational sites.
NYMX: 2.43 (-0.11)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 85

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
Avoid FOGs: Illinois Water's Holiday PSA

Updated Category News Views 0

Don't Ignore the Kitchen Sink This Holiday You ever poured something down the drain and just prayed it wouldn't come back to bite you later? Well, Illinois American Water is throwing up a big, red flag about doing exactly that during the holidays. When we're all busy passing the gravy boat and diving into festive feasts, it's easy to forget the after-party might just turn...

Continue Reading
Atomera Preps for Key Craig-Hallum Conference

Updated Category News Views 59

Unpacking the NYC Gathering Alight, let's comb through the moving parts here. Atomera Inc., ticker NASDAQ: ATOM for those eyeing the dance of numbers, is all set to step into the limelight at the 17th Annual Craig-Hallum Alpha Select Conference on November 17, 2026. This shindig isn't just another date on the calendar; it's a strategic haunt where Atomera will rub...

Continue Reading
Sovereign Crown Vault's Auction Draws Numismatic Collectors

Updated Category News Views 33

A Legendary Auction with Three Generations of Passion Coins, eh? They might just be small metallic disks to the untrained eye, but these suckers tell stories that stretch beyond any bank ledger. Sovereign Crown Vault LLC knows this, and they’re gearing up for quite the show on November 22, 2026. Their Holiday Season Kickoff Spectacular is about to lure in collectors...

Continue Reading
Halfday Iced Tea Shakes Up U.S. Retail Scene

Updated Category News Views 59

Halfday's Meteoric Rise in the U.S. Market Sometimes, you pick up a can of iced tea, and it just changes the game. That’s exactly what Halfday is doing, stepping on the accelerator and leaving traditional iced tea brands in the dust. With their latest announcement, they've snagged the title of the fastest-growing modern tea brand in U.S. multi-outlet retail. It's the...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 125

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 88

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Engrain's Geospatial Innovation Pushes Property Mapping Forward

Updated Category News Views 57

Pushing the Boundaries of Property Mapping How far can you expand the boundaries of property mapping tech? Well, Engrain seems hell-bent on finding out by cranking their innovations up a notch. The Denver-based stalwart in interactive mapping is rolling out some mind-boggling enhancements that could redefine how the multifamily housing sector operates. This isn't just...

Continue Reading
Ozelle Unveils AI-Powered Hematology Tool at MEDICA 2026

Updated Category News Views 97

Pioneering a New Era in Hematology In the fast-paced world of blood analysis, standing still means being left in the dust. Ozelle, with its AI-powered innovative tool, is making waves at MEDICA 2026 in Düsseldorf. Meet O-Cyte 1, an automated hematology analyzer that's merging high-resolution cell imaging with routine CBC (Complete Blood Count) testing. Sounds like...

Continue Reading
Univers Partners to Propel Physical AI Across Industries

Updated Category News Views 95

Univers Sets Sights on Global Physical AI Expansion Now here's a tune we've been humming for a while—AI is coming to take over the mundane, and Univers seems to think it's got the right band together to make that a full-blown concert in the built environment. Announced right in the heart of Antalya, Türkiye, at the esteemed COP31, we're seeing Univers grab hands with...

Continue Reading

Top 5 Most Recently Viewed Articles

Apirone's Transformative Year: Innovations and Achievements

Updated Category News Views 120

Apirone's Transformative Year: Innovations and Achievements As we reflect on the recent progress made by Apirone, a leading cryptocurrency services provider, it is clear that 2025 marked a groundbreaking year in the company’s evolution. With a steadfast commitment to fostering innovation and enhancing user engagement, Apirone has undertaken a series of pivotal...

Continue Reading
Green Rain Energy Enhances Capital Structure with Share Swap

Updated Category News Views 170

Green Rain Energy Takes Strategic Steps to Strengthen Capital Structure Green Rain Energy Holdings Inc. (OTCID: GREH) has made an announcement that reflects its commitment to enhancing shareholder value and addressing market dynamics. The Chief Executive Officer, Alfredo Papadakis, plans to cancel 310 million common shares held through a holding company. This bold move...

Continue Reading
Piper Sandler's Positive View on Webster Financial's Potential

Updated Category News Views 92

Positive Insights from Piper Sandler on Webster Financial Piper Sandler has reaffirmed its Overweight rating on Webster Financial Corporation (NYSE: WBS), setting a steadfast price target of $54.00. This rating reflects confidence in the bank's potential for recovery and growth, despite recent challenges faced by the company. Current Performance Analysis Despite a...

Continue Reading
City Furniture's Grand Opening Sparks Growth in Tampa Region

Updated Category News Views 158

City Furniture Celebrates Exciting Grand Opening CITY Furniture, a leading home furnishings retailer, has celebrated the successful grand opening of its expansive 120,000-square-foot showroom in Sarasota. This event not only marks a significant milestone in the company's growth but also embodies its commitment to transforming the home shopping experience in the Tampa...

Continue Reading
Celebrating Scott Alexander Rose as a Pinnacle Achiever in 2024

Updated Category News Views 238

Scott Alexander Rose Recognized as a Pinnacle Achiever 2024 Scott Alexander Rose has been prominently featured and acknowledged as a Pinnacle Achiever 2024 for his exemplary contributions to education and philanthropy. His dedication reflects a lifetime of service and commitment to making a meaningful impact. A Commitment to Education and Excellence Dr. Rose's academic...

Continue Reading